http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
1 online resource (xv, 398 pages) : illustrations
Cancer and Chemotherapy, Volume III: Antineoplastic Agents is a collection of articles that deals with the treatment of cancer using drugs. The collection describes the various drugs that are used, the therapeutic approaches being taken, and agents that are being developed. Part I is a general review of anti-cancer drugs as regards their action mechanisms, pharmacokinetics, pharmacology, known toxicities, and clinical utility. These drugs include alkylating agents such as mitomycin C and nitrosoureas; plant alkaloids such as maytansine; antibiotics such as anthracyclines; platinum-containing.
Front Cover; Antineoplastic Agents; Copyright Page; Table of Contents; General Preface; Preface to Volume III; Part I: General Reviews; CHAPTER 1. NUCLEOSIDE ANALOGUES; I. INTRODUCTION; II. CYTOSINE ARABINOSIDE; III. 5-AZACYTIDINE; IV. 5-FLUOROURACIL; V. OTHER 5-FLUORO PYRIMIDINES; VI. 3-DEAZAURIDINE; VII. PURINE ANALOGUES; VIII. ARABINOSYL ADENINE; REFERENCES; CHAPTER 2. CYCLOPHOSPHAMIDE AND ANALOGUES; I. INTRODUCTION; II. STRUCTURE AND METABOLISM; III. CLINICAL PHARMACOLOGY; IV. TOXICITIES; V. CLINICAL ACTIVITY AND DOSE SCHEDULES; VI. ANALOGUES; REFERENCES; CHAPTER 3. NITROSOUREAS.
I. introductionii. decomposition and metabolism; iii. mechanism of action; iv. clinical use; v. clinical toxicities; references; chapter 4. mitomycin c-an overview; i. introduction; ii. chemistry; iii. structure-activity relationships; iv. molecular pharmacology; v. pharmacology; vi. clinical effects; vii. conclusions; references; chapter 5. other alkylating agents; i. introduction; ii. mechanism of action; iii. other alkylating agents; iv. conclusions; references; chapter 6. the vinca alkaloids and similar compounds; i. the vinca alkaloids; ii. the podophyllotoxin derivatives.
Iii. maytansinereferences; chapter 7. bleomycin-an overview; i. introduction; ii. chemistry; iii. molecular pharmacology; iv. clinical pharmacology; v. clinical activities; vi. clinical toxicities; vii. conclusions; references; chapter 8. the anthracyclines; i. introduction; ii. chemistry; iii. molecular pharmacology; iv. clinical pharmacology; v. clinical activities of adriamycin and daunorubicin; vi. toxicities of adriamycin; vii. anthracyclines in development; references; chapter 9. cisplatin and analogues: a new class of anticancer drugs; i. introduction.
Ii. antitumor activity in animal tumorsiii. animal toxicology; iv. efficacy; v. toxicity; vi. cisplatin analogues; vii. conclusion; references; chapter 10. investigational cancer drugs; i. introduction; ii. alkylating agents; iii. anthracycline analogues; iv. tubulin binding agents; v. antitumor antibiotics; vi. nitrosoureas; vii. antimetabolites; viii. miscellaneous; ix. summary; references; chapter 11. hormone therapy; i. basis of endocrine therapy; ii. prostatic cancer; iii. breast cancer; iv. cancer of the uterine endometrium; v. lymphomas; vi. summary; references.
CHAPTER 12. A HUMAN TUMOR STEM CELL SYSTEM: CONCEPTS, METHODOLOGY, AND APPLICATIONI. INTRODUCTION; II. METHODOLOGY; III. APPLICATIONS; IV. CONCLUSIONS; REFERENCES; Part II: Molecular Pharmacology of Selected Antineoplastic Agents; CHAPTER 13. THE MOLECULAR PHARMACOLOGY OF BLEOMYCIN; I. INTRODUCTION; II. CHEMISTRY; III. THE INTERACTIONS OF METALS WITH BLEOMYCIN AND ANALOGUES; IV. EFFECTS OF BLEOMYCIN ON ISOLATED DNA; V. CELLULAR EFFECTS; VI. EFFECTS ON THE CELL CYCLE; VIL MORPHOLOGICAL EFFECTS; Vili. INTRACELLULAR FATE AND METABOLISM; IX. CONCLUSIONS; REFERENCES.
edited by Stanley T. Crooke, Archie W. Prestayko, editorial assistant Nancy Alder.
Includes bibliographical references and index.